Clinical study on Efficay of Biological Disease-Modifying Rheumatic Drug spacing -multicenter cohort-

Clinical study on Efficay of Biological Disease-Modifying Rheumatic Drug spacing -multicenter cohort- - Stuy on efficay of bDMARD spacing

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034567

Enrollment

190

Registered

2018-10-19

Start date

2017-03-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Rheuamtoid arthritis on EULAR2010 criteria 2. RA activity maintained low disease activity or remission over 3 months treated with golimumab or tocilizumab or abatacept 3. Dose inteval period extended by 1.5 times on golimumab, tocilizumab or abatacept 4. be able to follow up over 60 weeks

Exclusion criteria

Exclusion criteria: Patients discontinuing therapy for adverse reactions and those withdrawing for reasons unrelated to the drugs

Design outcomes

Primary

Measure	Time frame
Period of low disease activity by CDAI	—

Secondary

Measure	Time frame
Back ground factor for maintained low disease activity	—

Countries

Japan

Contacts

Public ContactHiroaki Matsuno

Matsuno Clinic for Rheumatic diseases Rheumatology

info@toyama-ra.com076-436-1757

Outcome results